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Intermittent claudication caused by infrainguinal arterial
disease can mostly be treated conservatively. Yet, when functional
capacity is threatened, claudication may need to be treated by
revascularisation. This should not be done too hastily as any kind of
revascularisation may be an onset of a vicious cycle of repeated
interventions, whichmay accelerate the otherwise benign course of
PAD.1 Furthermore, scientiﬁc evidence is lacking concerning the
efﬁcacy of endovascular therapy on claudication.2Chronic Critical Ischemia
Patients with critical limb ischemia (CLI) represent less than 5%
of symptomatic peripheral arterial disease. In younger age groups,
CLI is encountered typically in diabetics and there are a number of
ischemic and neuro-ischemic lesions in this group of patients
which do not meet the strict deﬁnition of CLI. The risk for ampu-
tation at a metatarsal or higher level is 8-fold higher in diabetics
compared to nondiabetics.3 Additionally, type I diabetics reach
a 86-fold increased risk for any nontraumatic amputation below
the age of 65 years.4 In addition, despite revascularization, ischemic
lesions have a slow tendency for healing in diabetics.5 In this
patient group the 5-year survival of patients<65 years old was 60%
while it was 48% in older patients in Helsinki.
This is why a durable revascularisation should be used to allow
wound healing in this young group of patients. In-line arterial ﬂow
to the pedal level offers the best results in patients with CLI as
shown by the 10-year data from Pomposelli et al. with results from
1032 limb salvage bypasses to dorsalis pedis artery in 865 patients.6
In this study, the patency of saphenous vein grafts was better than
any other conduit with a secondary patency rate of 67.6% at 5 years.6
No comparable data are available for endovascular treatment.q Age is an issue. Younger patients have longer life expectancy and thus need
more durable treatment solutions. Out of 1725 consecutive infrainguinal revascu-
larisations for symptomatic peripheral arterial disease (PAD) in Helsinki University
Central Hospital, as many as 482 (28%) belonged to this group of patients <65 years
of age.
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Patency is a direct measure of revascularisation success when
reopening or bypassing occlusions. Patency is the key criterion for
judging the primary effectiveness of a revascularization but less
often described than leg salvage and amputation-free survival, or
even wound healing, quality of life and sustained ambulation.
Patient-related outcomes are, of course, important but strongly
affected by other measures than treatment modality itself.
Leg Survival or Leg Salvage
Leg salvage or foot preservation, a favoured and easy to retrieve
endpoint of CLI studies, is problematic as a number of factors other
than revascularisation affect the outcome. Leg salvage is an indirect
measure of the success of revascularisation. The key question is
what the leg outcome would be if untreated or treated conserva-
tively. Indeed, in studies reporting outcome of patients with CLI
unsuitable for revascularisation, one year leg survival rates of 54%
(CLI veriﬁed by ankle pressure <50 mmHg or toe pressure
<30 mmHg),8 58% for controls with spinal cord stimulation9 and
66% in patients with ABI<0.510 were reported. In this last study,
Marston et al10 reported a wound healing rate of 52% at one year.
The results of any revascularisation should be compared with
these data. Four large recent series of bypass surgery for CLI
reported leg salvage rates of 88e92% at one year.6,11e13 In these
series, a 5-year leg salvage rate of 78% underlines the durability of
bypass surgery.6 Endovascular treatment has been found to have
82e86% leg salvage rates at one year.14,15 Lu et al.16 summed up the
limited experience available in using distal venous arterialisation as
the last resort procedure to avoid major amputation and even that
method was associated with 71% leg salvage at one year (Fig. 1).
Mind the Gap!
We should be careful when considering the so-called patency/
leg-salvage gapwhich seemswider in endovascular than in surgical
series, i.e. occlusion of the revascularized segment leads to ampu-
tation less often after endovascular procedure than surgical bypass
as summarized by Romiti et al.14 This gap can be explained in
different ways. One hypothesis is that leg salvage exceeding theed by Elsevier Ltd. All rights reserved.
Figure 1. One-year leg survival after different modes of treatment for CLI (data from
references [8e10] for conservative treatment, [9] for spinal cord stimulation, [16] for
venous arterialization, [14e15] for PTA and [11e13] for bypass).
Figure 2. One-year leg salvage after different modes of treatment for CLI (leg salvage
attributable to patent revascularization shown as shaded area of the column). Data
from references [9] for spinal cord stimulation, [16] for venous arterialization, [14e15]
for PTA and [11e13] for bypass).
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early patency which provides adequate perfusion until ischemic
lesions are healed. Thereafter the leg stays viable if infection is
cleared and proper foot care sustained, especially with diabetic
lesions. This concept may, of course, be partly true, but a more
obvious explanation is that legs treated by endovascular methods
have milder lesions as illustrated for instance by the impressive
results of Faglia et al.17 Leg salvage is actually the improvement
achieved by therapeutic measures above natural leg survival
(Fig. 2).Apples and Oranges
Percutaneous transluminal angioplasty (PTA) was recommended
for stenosis, and bypass for occlusions in the ﬁrst TASC Document.18Table 1
Summary of recommendations of the TransAtlantic Inter-Society Consensus II Working G
Level of disease Segment/recommendation
Usually PTA (type A) PTA preferred
(type B)
Sur
(typ
Femoropopliteal SFA stenosis 10 cm
or occlusion 5 cm
SFA stenosis or
occlusion 15 cm;
popliteal stenosis
SFA
rec
Crural Nonea Nonea Ste
Outcomes Excellentb Excellentb PTA
and
con
pat
a Crural interventions have severe outcomes if they go wrong; therefore there is no ty
b Excellent results can be expected from an endovascular approach in all segments.In the second TASC Document,19 PTA was still recommended for
stenosis and bypass for long occlusions, but there was no consensus
on therapy for short and moderate occlusions (Table 1). Endovas-
cular therapy for infrapopliteal arterial disease is gaining acceptance
as a ﬁrst-line method to improve ulcer healing and limb salvage,
despite lack of evidence. In a recent meta-analysis on infrapopliteal
surgery and infrapopliteal endovascular interventions11,14 with 29
and 30 studies included respectively, 88% of patients were diabetics
and 88% had tissue loss among the bypass group (n¼ 2320),whereas
61% were diabetics and 76% had tissue loss among the endovascular
group (n ¼ 2653). No distal pressure measurement was available in
this study. Primary and secondary mid-term patency rates were
better after bypass, but there was no difference in limb salvage. The
results of this meta-analysis are biased by the heterogeneity of
indications, risk factors, number of treated arterial segments, lesion
type (occlusion vs. stenosis), lesion length, lesion characteristics, and
outﬂow. In this setting, TASC II classiﬁcation of femoropopliteal
lesions is not very helpful.20 Furthermore, many studies are ﬂawed
for a number of other reasons.21,22 It ismost likely that bypass groups
include patients with more severe disease and only a rather small
share of infrainguinal lesions are equally well treatable with either
method (Table 1).
Data from Randomised Controlled Trials (RCT)
When both endovascular and surgical revascularisation are
technically feasible, no signiﬁcant difference was observed in
symptomatic relief in the few RCT which included both supra- and
infrainguinal revascularisations for mixed indications.2 There are
two RCTs including mostly claudicants with superﬁcial femoral
artery (SFA) occlusions, which suggest that surgical bypass gives
better results than the endovascular approach.23,24 Another
RCT(25,26) including a large variety of lesions and mixed indica-
tions observed similar outcome after both approaches (Table 2).
The British Angioplasty vs. Surgery in Ischaemic Legs Trial
(BASIL) is the only large RCT comparing endovascular revascular-
isation and bypass surgery.27 Only patients with CLI or at least
severe ischemia and potential candidates for either infrainguinal
angioplasty or bypass were included. In this trial, 42% of patients
were diabetics. Both approaches yielded similar results in terms of
amputation-free survival up to two years. Surgery was associated
with higher postoperative morbidity, more hospital days and
higher costs and angioplasty was associated with higher need for
further revascularisation procedures.27 However, the long term
results suggested that surgical repair was more durable28 but no
patency data was available. The results of BASIL Trial emphasize the
role of bypass over PTA in ﬁt patients with a saphenous vein
available28 and this was the case in 75% of the patients in BASIL
Trial.roup.22
gery preferred
e C)
Usually surgery (type D)
stenosis or occlusion >15 cm;
urrent disease
Complete SFA or popliteal occlusions
noses 4 cm or occlusions 2 cm Diffuse disease or occlusions >2 cm
/stent only has modest results
is indicated when surgery is
traindicated for technical or
ient reasons.
Endovascular approach is not advised
unless symptoms are limb threatening
and surgery is not possible.
pe A or B recommendation.
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M.J.A. Lepäntalo / European Journal of Vascular and Endovascular Surgery 44 (2012) 112e115114The generalizability of the BASIL Trial was audited from a sample
of 456 patients with infrainguinal lesions, 236 of whom underwent
a revascularization procedure but only 29% of them were suitable
for randomization, i.e. treatment by either method. This ﬁnding
illustrates the narrow overlap of the indications for endovascular
and surgical revascularization.
The same holds particularly true with the Scandinavian Thru-
pass vs. Bypass Study, in which SFA occlusions were randomised
between PTFE endografting and PTFE bypass grafting.24 Only 4% of
the SFA occlusionsmet the tight inclusion criteria chosen to exclude
short occlusions and all lesions with unfavourable landing zones for
an endograft. This illustrates the difﬁcult balance between internal
and external validity. But when comparable patients are analysed,
bypass seems to give a better result.23,24,28 These data are far less
cited than those suggesting non-inferiority of endovascular
methods (Table 2).
The ﬁndings of BASIL Trial suggest that whether to perform
bypass or PTA ﬁrst for CLI due to infrainguinal disease depends on
life expectancy.28 Long-term results favouring bypass were also
observed in a large cohort study of 858 CLI patients with
a propensity score analysis.29
Complications and Costs
Admittedly, bypass surgery is followed by a number of peri-
operative and late complications. Recently LaMuraglia et al30
reported a high incidence of complications related to bypass
surgery according to an American private sector database with 2.7%
mortality and 18.7% major complications including 7.4% of graft
thrombosis. In this extended series, complications were associated
with age>80 years and poor preoperative functional status.31 Thus
it is difﬁcult to use these data directly to assess the risk of bypass for
patients<65 years. The complications of PTA are said to be rare and
minor and not to preclude a bypass at a later date. Yet, crural
interventions may have severe non-correctable outcomes.22
Furthermore, technical failure rates of 20% are associated with
attempts to open infrapopliteal occlusions32 and procedural
complication rates of 7e17% have been reported.14,15,31 Further-
more, an early death rate of 2.7% in a mixed series indicated that
crural PTA ﬁrst strategy is not without risk.33 Finally the main
predictor of outcome is not the approach used, but the risk proﬁle
of the patient. According to the BASIL Trial,28 surgery was associ-
ated with higher number of days in hospital and the need for
advanced postoperative care. The mean cost of inpatient treatment
was by a third higher for bypass ﬁrst than for PTA ﬁrst strategy but
this was true only during the ﬁrst year. After two years the cost of
repeated new interventions abolished this difference.28 In addition,
it is unclear what the costs of unnecessary interventions are.
Loss of ambulation is also an important cause of increase in
costs. Goodney et al reported a 81% sustained ambulation rate at
one year in patients treated by bypass for CLI.12
The approaches to maximize early detection and optimize
therapy for PAD have been emphasized in the literature with the
hope to lessen the number of patients with CLI.34 This is absolutely
true for risk factors and best medical treatment, but there is no data
to show that indications for revascularisations should be extended.
Regional data from southern Finland have shown that endovascular
activity for CLI has been doubled during the past 5 years but
without any positive effect on major amputation rates. An inter-
esting, though biased analysis could bemade using the present data
to assess the effectiveness of the current practice (Figs. 1 and 2). To
save one leg for a year, 3-4 legs should be treated by bypass oper-
ations and 6-7 legs by endovascular interventions. Indeed, scientiﬁc
evidence is lacking to assess the true efﬁcacy of endovascular
therapy on critical ischemia.2
M.J.A. Lepäntalo / European Journal of Vascular and Endovascular Surgery 44 (2012) 112e115 115Conclusions
The aim is always to revascularize the leg properly, in CLI with
resulting well perfused foot to allow ulcer healing. A durable
solution can be achieved by bypass using good quality saphenous
vein and by ascertaining good outﬂow. Bypass surgery and endo-
vascular interventions are complementary techniques for revas-
cularization. If endovascular and bypass procedure were possible
with equal outcomes, then endovascular treatments would be
preferred. However the main issue, especially in younger patients,
is the durability of the revascularisation, better to trust a bypass
with a good vein to an artery with good outﬂow. Despite early
peripheral arterial disease in patients <65 years old, the longevity
is not shortened to an extent to allow the second best treatment of
choice to be selected.
Endovascular techniques and equipment are developing rapidly
but scientiﬁc evidence of these new methods is scarce. Level one
evidence concerning subintimal angioplasty, drug eluting balloon,
cryoplasty and other latest endovascular innovations do not exist.
When available, scientiﬁc data includes mainly short case-series,
and since new techniques are introduced all the time, the target
is moving too rapidly to collect proper scientiﬁc data.
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